Studi Farmakovigilans Penggunaan Obat Antiretriviral di Puskesmas Semarang
Abstract
The increase in cases of the HIV epidemic in Indonesia at the end of 2009 continued to increase, it is estimated that around 332.200 people are living with HIV. This figure has almost doubled from 2005 as many as 170.000 people living with HIV. Provision of extensive anti-retroviral therapy (ART) also result in mutations of the HIV virus that can lead to resistance. The purpose of this study was to determine the description and incidence of unwanted drug reactions in patients who were prescribed antiretroviral drugs and to assess the quality of life of patients who had received anti-retroviral drug prescriptions at the public health center. This type of research is a descriptive observational study, data collection was carried out retrospectively on patients who received herbal medicine at the public health center. The sampling technique in this study was quota sampling with a research instrument in the form of ROTD interview sheets taken from the Naranjo algorithm. The results showed that the use of antiretroviral drugs (ARVs) would cause unwanted drug reactions such as nausea, vomiting, dizziness (vertigo) which were categorized as possibilities and possibilities.
References
National AIDS Commission. 2009. Republic of Indonesia Country Report on the Follow up the Declaration of Commitment on HIVAIDS (UNGASS) Reporting Period 2008- 2009.
National AIDS Commission. 2. National AIDS Commission. 2007. National AIDS Commission 2007-2010 HIV and AIDS Response Strategies.
Riyarto S, Hidayat B, Johns B, Probandari A, Mahendradhata Y et al. 2010. The financial burden of HIV care, including antiretroviral therapy, on patients in three sites in Indonesia. Oxford University Press, Health Policy and Planning 2010;25: 272-282.
JOTHI. 2010. Akses Obat ARV di Indonesia sebagai upaya penjaminan kesehatan masyarakat dan membangun perlindungan sosial ekonomi dalam penanggulangan AIDS. www.jothi.or.id : diakses 30 Mei 2011
Pingen M,Wensing AMJ,Fransen K, De Bel A, de Jong D, Hoepelman AIM, et al. Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. Retrovirology. 2014;11:105–120 5.
Menendez-Arias L. Mutation rate and intrinsic fidelity of retroviral reverse transcriptases. Viruses, 2009; 1(3):1137–1165. doi: 10.3390/ v1031137
Avihingsanon, Anchalee, Wirach Maek-a-nantawat, and Sivaporn Gatechompol. 2017. “International Journal of Infectious Diseases Ef Fi Cacy and Safety of a Once-Daily Single-Tablet Regimen of Tenofovir , Lamivudine , and Efavirenz Assessed at 144 Weeks among Antiretroviral-Naïve and Experienced HIV-1-Infected Thai Adults $ , $$.” International Journal of Infectious Diseases 61. International Society for Infectious Diseases: 89–96. https://doi.org/10.1016/j.ijid.2017.06.009.
Poupard, M, N F Ngom Gueye, D Thiam, B Ndiaye, P M Girard, E Delaporte, P S Sow, and R Landman. 2007. “Quality of Life and Depression among HIV-Infected Patients Receiving Efavirenz- or Protease Inhibitor-Based Therapy in Senegal,” 92–95.
Sanjay Pujari*, Ameet Dravid, Nikhil Gupte, Kedar Joshix and Vivek Bele. 2008. “Journal of the International AIDS Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir / Emtricitabine / Efavirenz in HIV-1-Infected Patients in” 6: 6–11. https://doi.org/10.1186/1758-2652-10-8-196.
Swartz, J E, L Vandekerckhove, H Ammerlaan, A C De Vries, J Begovac, W F W Bierman, C A B Boucher, et al. 2015. “Efficacy of Tenofovir and Efavirenz in Combination with Lamivudine or Emtricitabine in Antiretroviral-Naive Patients in Europe,” no. March: 1850–57. https://doi.org/10.1093/jac/dkv033.